It should be noted that CBFβ–SMMHC function in the LIC of CML-chronic phase (i.e., with active proliferative signals) or post-therapy HSCs/MDS (i.e., with higher mutation content) may involve different targets. Here, CBFB is linked to chronic myelogenous leukemia, BCR-ABL1 positive.